S
Sarai Cordoba
Publications - 2
Citations - 63
Sarai Cordoba is an academic researcher. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 16 citations.
Papers
More filters
Journal ArticleDOI
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Antje Neeb,Nicolás Herranz,Sara Arce-Gallego,Susana Miranda,Lorenzo Buroni,Wei Yuan,Alejandro Athie,Teresa Casals,J. Carmichael,J. Carmichael,Daniel Nava Rodrigues,Bora Gurel,Pasquale Rescigno,Pasquale Rescigno,Jan Rekowski,Jon Welti,Ruth Riisnaes,Veronica Gil,Jian Ning,Verena Wagner,Irene Casanova-Salas,Sarai Cordoba,Natalia Castro,Maria de Los Dolores Fenor de la Maza,Maria de Los Dolores Fenor de la Maza,George Seed,Khobe Chandran,Khobe Chandran,Ana Ferreira,Ines Figueiredo,Claudia Bertan,Diletta Bianchini,Diletta Bianchini,Caterina Aversa,Caterina Aversa,Alec Paschalis,Alec Paschalis,Macarena Gonzalez,Rafael Morales-Barrera,Cristina Suarez,Joan Carles,Amanda Swain,Adam Sharp,Adam Sharp,Jesús Gil,Violeta Serra,Christopher J. Lord,Suzanne Carreira,Joaquin Mateo,Johann S. de Bono,Johann S. de Bono +50 more
TL;DR: This data indicates that ATM loss in PC is not always detected by targeted NGS, associates with genomic instability, and is most sensitive to combined ATR and PARP inhibition.
Journal ArticleDOI
A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naïve prostate cancer (mHNPC): ZZFIRST.
Joaquin Mateo,Angel Borque,Daniel Castellano,Elena Castro,Miguel Angel Climent Duran,Albert Font,David Lorente,Begoña Mellado,Alejo Rodriguez-Vida,Merce Cuadras,Jacques Planas,I. Casanova Salas,Sarai Cordoba,Lucila González,Marta Martínez de Falcon,M.E. Elez Fernandez,Miguel Sampayo-Cordero,Andrea Malfettone,Raquel Perez-Lopez,Joan Carles +19 more
TL;DR: The ZZFIRST trial is evaluating the combination of TALA –a poly(ADP-ribose) polymerase inhibitor– and EZ –an AR signaling inhibitor– in mHNPC patients and PSA-complete response defined as the percentage of patients with PSA < 0.2 ng/mL at 12 months of therapy.